sanofi bid goes hostile , page-5

The second article in my post states;

"We think that Genzyme sees its billions coming from raising the price of this relatively inexpensive drug to the price shared by the drug, Gilenya (which was first synthesized in 1992 for use in organ transplants),which is the most expensive Multiple Sclerosis treatment available at $48,000 per year."

So sky, it's a relatively inexpensive drug that can be hiked up!
I'm sure SA would have done their homework pre purchase.

Lemtrada's in stage III trials on an FDA fast track program and possibly due out late 2012, with this date it still could miss our prefill, due to the 2013 aging validation thingy?? :-(